Takeda Pharmaceuticals' Ling Wang Talks Model-based Dose-finding Designs

Posted by Cytel

Nov 16, 2015 4:30:00 PM

 

A popular trend in current dose-finding studies moves away from traditional rule-based study designs (e.g. 3+3) and instead uses model-based designs to make dosing decisions during a trial. In this video from Cytel and Sanofi/Genzyme's single day forum on early phase oncology studies, Ling Wang of Takeda Pharmaceuticals gives a talk on single-agent and combination dose-finding designs.

Related Items of Interest

[1] Bayesian Dose Escalation Designs for Late Onset Toxicity

[2] 2 Talks on Early Phase Go/No-GO Decision Making

 

Topics: Dose-Finding, BLRM

The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.

 

Posts by Topic

see all

Recent Posts